Clovis Oncology Inc. (NASDAQ:CLVS) shares were up 5.1% during mid-day trading on Thursday after Stifel Nicolaus raised their price target on the stock from $30.00 to $45.00. Stifel Nicolaus currently has a buy rating on the stock. Clovis Oncology traded as high as $37.97 and last traded at $37.51, with a volume of 3,535,686 shares trading hands. The stock had previously closed at $35.68.

A number of other research analysts have also issued reports on CLVS. Vetr lowered shares of Clovis Oncology from a “strong-buy” rating to a “buy” rating and set a $17.66 target price on the stock. in a report on Wednesday, May 25th. Credit Suisse Group AG reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Wednesday, June 8th. Piper Jaffray Cos. reaffirmed a “hold” rating and set a $14.00 price objective on shares of Clovis Oncology in a research note on Wednesday, June 29th. SunTrust Banks Inc. initiated coverage on shares of Clovis Oncology in a research note on Friday, August 5th. They set a “buy” rating and a $25.00 price objective for the company. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $13.00 price objective on shares of Clovis Oncology in a research note on Tuesday, August 9th. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $32.20.

A number of institutional investors have recently added to or reduced their stakes in CLVS. Fox Run Management L.L.C. bought a new position in Clovis Oncology during the second quarter worth $154,000. Kazazian Asset Management LLC bought a new position in Clovis Oncology during the first quarter worth $282,000. Bellevue Group AG bought a new position in Clovis Oncology during the first quarter worth $1,008,000. Schonfeld Strategic Advisors LLC bought a new position in Clovis Oncology during the first quarter worth $233,000. Finally, Boston Partners bought a new position in Clovis Oncology during the second quarter worth $1,540,000. Hedge funds and other institutional investors own 98.46% of the company’s stock.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/clovis-oncology-inc-clvs-shares-up-5-1-following-analyst-upgrade.html

The company’s market capitalization is $1.46 billion. The firm has a 50-day moving average price of $22.84 and a 200-day moving average price of $17.30.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.13) by $0.06. During the same period last year, the business earned ($2.10) EPS. On average, equities analysts forecast that Clovis Oncology Inc. will post ($9.32) earnings per share for the current year.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

5 Day Chart for NASDAQ:CLVS

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.